The S&P 500 jumped 2.1% on Friday, March 14, wrapping up a volatile week as government shutdown concerns eased.

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Philadelphia-based Endo sold its international pharma unit to Knight Therapeutics this week for up to $99 million, while Ireland-headquartered Mallinckrodt sold Therakos, a specialist in ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for 2seventy bio ...

The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.